Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases

Ann Rheum Dis. 2021 Oct;80(10):1365-1366. doi: 10.1136/annrheumdis-2021-221145. Epub 2021 Aug 24.

Affiliations

¹ Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
² Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
³ Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
⁴ Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA dorry@jhmi.edu.
⁵ Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

^# Contributed equally.

No abstract available

Keywords: COVID-19; antirheumatic agents; autoimmune diseases; epidemiology; vaccination.

Publication types

Letter
Comment

MeSH terms

Antibody Formation
COVID-19 Vaccines
COVID-19*
Humans
Musculoskeletal Diseases*
SARS-CoV-2

Substances

COVID-19 Vaccines

Grants and funding